Cardiovascular – Renal Drugs : Antihypertensive : Angiotensin-converting Enzyme Inhibitors (ACEI)
ORAMI1 “Ramitace capsule” 2.5 mg/cap
OTRIT1 “Tritace tablet” 2.5 mg/tab
適應症：高血壓、心肌梗塞後的心衰竭，降低因心血管疾病導致之心肌梗塞、中風及死亡的危險。
Usual dose:
Cardiovascular event risk, Reduction:
Adult: initial, 2.5 mg qd for 1 wk followed by 5 mg qd for 3 wks; maintenance, 10 mg (if tolerated) qd or in 2 divided doses.
Congestive heart failure-Myocardial infarction:
Adult: initial, 1.25-2.5 mg bid for 1 wk; maintenance, 5 mg (if tolerated) bid, dose titration at 3-wk intervals.
Hypertension:
Adult: (in p’ts not receiving a diuretic) initial, 2.5 mg qd; maintenance, 2.5-20 mg qd or in 2 divided doses, lower initial dose to 1.25 mg daily if given with diuretics.
Dose adjustment:
Renal impairment: CrCl > 30 ml/min, initially 2 mg/day, max. 8 mg/day.
Geriatric: 4 mg in 1-2 divided doses; caution with doses >8 mg daily.
Contraindication: See quinapril.
Adverse effect:
Common: hypotension, hyperkalemia, nausea, dizziness, cough
Serious: intestinal angioedema, liver failure, angioedema